Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.
Boyiadzis MM, Aksentijevich I, Arber DA, Barrett J, Brentjens RJ, Brufsky J, Cortes J, De Lima M, Forman SJ, Fuchs EJ, Fukas LJ, Gore SD, Litzow MR, Miller JS, Pagel JM, Waller EK, Tallman MS. Boyiadzis MM, et al. Among authors: miller js. J Immunother Cancer. 2020 Oct;8(2):e000810. doi: 10.1136/jitc-2020-000810. J Immunother Cancer. 2020. PMID: 33077513 Free PMC article.
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.
Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS. Cooley S, et al. Among authors: miller js. Blood. 2010 Oct 7;116(14):2411-9. doi: 10.1182/blood-2010-05-283051. Epub 2010 Jun 25. Blood. 2010. PMID: 20581313 Free PMC article.
Use of allogeneic NK cells for cancer immunotherapy.
Geller MA, Miller JS. Geller MA, et al. Among authors: miller js. Immunotherapy. 2011 Dec;3(12):1445-59. doi: 10.2217/imt.11.131. Immunotherapy. 2011. PMID: 22091681 Free PMC article. Review.
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J. Weisdorf D, et al. Biol Blood Marrow Transplant. 2012 Jun;18(6):937-43. doi: 10.1016/j.bbmt.2011.11.024. Epub 2011 Dec 7. Biol Blood Marrow Transplant. 2012. PMID: 22155505 Free PMC article. Clinical Trial.
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS. Wiernik A, et al. Among authors: miller js. Clin Cancer Res. 2013 Jul 15;19(14):3844-55. doi: 10.1158/1078-0432.CCR-13-0505. Epub 2013 May 20. Clin Cancer Res. 2013. PMID: 23690482 Free PMC article.
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS. Gleason MK, et al. Among authors: miller js. Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20. Blood. 2014. PMID: 24652987 Free PMC article.
1,124 results